title: Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes.
abstract: To investigate the anti-atherogenic effect of metformin, we prospectively evaluated the effect of metformin treatment on common carotid intima-media thickness (CCA-IMT) in patients with type 2 diabetes. A 2-year open prospective study was performed. Thirty-six patients were treated with metformin (500-750 mg per day). CCA-IMT was measured after 1- and 2-year treatment. Changes in CCA-IMT were compared with control patients. After 2-year metformin therapy, the progression of CCA-IMT was significantly less than 56 control patients (0.02+/-0.08 mm versus 0.07+/-0.08 mm, P<0.01). Metformin therapy did not alter body weight, blood pressure, HbA1c, and serum lipids relative to the control. Thus, metformin attenuates the progression of CCA-IMT. This anti-atherogenic effect is not mediated through changes in classical cardiovascular risk factors.
authors.affiliation: Diabetes Center, Sasebo Chuo Hospital, 15 Yamato-cho, Sasebo, Nagasaki 857-1195, Japan. dmkmatsu@hakujyujikai.or.jp
authors.forename: Kazunari
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Sera
authors.forename: Yasuyo
authors.initials: Y
authors.lastname: Abe
authors.forename: Tan
authors.initials: T
authors.lastname: Tominaga
authors.forename: Yukitaka
authors.initials: Y
authors.lastname: Yeki
authors.forename: Seibei
authors.initials: S
authors.lastname: Miyake
mesh_terms: D001161:Arteriosclerosis / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control; D002339:Carotid Arteries / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D002340:Carotid Artery Diseases / Q000150:complications / Q000188:drug therapy; D002908:Chronic Disease; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000473:pathology; D004035:Diet Therapy; D004334:Drug Administration Schedule; D005260:Female; D005907:Gliclazide / Q000627:therapeutic use; D005905:Glyburide / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000737:chemistry / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007564:Japan; D008297:Male; D008687:Metformin / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D011446:Prospective Studies; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D013997:Time Factors; D017539:Tunica Intima / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D017540:Tunica Media / Q000187:drug effects* / Q000473:pathology / Q000502:physiology
chemical_list: D005907:Gliclazide; D005905:Glyburide; D006442:Glycated Hemoglobin; D008687:Metformin; D013453:Sulfonylurea Compounds; C057619:glimepiride